Similar articles for PMID: 27080185

Year	Number of Results
1971	1
1999	1
2003	1
2005	5
2006	8
2007	1
2008	2
2009	7
2010	8
2011	3
2012	10
2013	10
2014	15
2015	7
2016	8
2017	4
2018	2
2019	2
2020	2
2021	2
2022	1
2024	0

1

Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.

Tian Y, Ma Y, Gibeau CR, Lahue BR, Shipps GW Jr, Strickland C, Bogen SL. Tian Y, et al. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2735-8. doi: 10.1016/j.bmcl.2016.03.078. Epub 2016 Mar 23. Bioorg Med Chem Lett. 2016. PMID: 27080185

2

Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.

Pan W, Lahue BR, Ma Y, Nair LG, Shipps GW Jr, Wang Y, Doll R, Bogen SL. Pan W, et al. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1983-6. doi: 10.1016/j.bmcl.2014.02.055. Epub 2014 Feb 28. Bioorg Med Chem Lett. 2014. PMID: 24656661

3

Substituted piperidines as HDM2 inhibitors.

Ma Y, Lahue BR, Shipps GW Jr, Brookes J, Wang Y. Ma Y, et al. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1026-30. doi: 10.1016/j.bmcl.2014.01.026. Epub 2014 Jan 17. Bioorg Med Chem Lett. 2014. PMID: 24486134

4

Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.

Carry JC, Garcia-Echeverria C. Carry JC, et al. Bioorg Med Chem Lett. 2013 May 1;23(9):2480-5. doi: 10.1016/j.bmcl.2013.03.034. Epub 2013 Mar 16. Bioorg Med Chem Lett. 2013. PMID: 23541651 Free article.

5

Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.

Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N. Noguchi T, et al. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3802-5. doi: 10.1016/j.bmcl.2013.04.094. Epub 2013 May 15. Bioorg Med Chem Lett. 2013. PMID: 23726030 Free article.

6

Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.

Plante JP, Burnley T, Malkova B, Webb ME, Warriner SL, Edwards TA, Wilson AJ. Plante JP, et al. Chem Commun (Camb). 2009 Sep 14;(34):5091-3. doi: 10.1039/b908207g. Epub 2009 Jun 24. Chem Commun (Camb). 2009. PMID: 20448956 Free PMC article.

7

Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.

Mondal C, Halder AK, Adhikari N, Saha A, Saha KD, Gayen S, Jha T. Mondal C, et al. Eur J Med Chem. 2015 Jan 27;90:860-75. doi: 10.1016/j.ejmech.2014.12.011. Epub 2014 Dec 8. Eur J Med Chem. 2015. PMID: 25535952

8

Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. Parks DJ, et al. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3310-4. doi: 10.1016/j.bmcl.2006.03.055. Epub 2006 Apr 4. Bioorg Med Chem Lett. 2006. PMID: 16600594

9

Diphenylpyrroles: Novel p53 activators.

Gomha SM, Eldebss TM, Abdulla MM, Mayhoub AS. Gomha SM, et al. Eur J Med Chem. 2014 Jul 23;82:472-9. doi: 10.1016/j.ejmech.2014.05.082. Epub 2014 Jun 3. Eur J Med Chem. 2014. PMID: 24934571

10

Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.

Tian Y, Lahue BR, Ma Y, Nair LG, Pan W, Doll RJ, Guzi T, Ma Y, Wang Y, Bogen SL. Tian Y, et al. Bioorg Med Chem Lett. 2022 Apr 1;61:128625. doi: 10.1016/j.bmcl.2022.128625. Epub 2022 Feb 11. Bioorg Med Chem Lett. 2022. PMID: 35158044

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

90 results

Results by year